During the past 12 months, Laboratorios Farmaceuticos Rovi's average EPS without NRIGrowth Rate was -13.50% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was 40.40% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 61.90% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 26.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 13 years, Laboratorios Farmaceuticos Rovi's highest 3-Year average EPS without NRI Growth Rate was 98.30% per year. The lowest was -10.40% per year. And the median was 10.40% per year.
Laboratorios Farmaceuticos Rovi EPS (Diluted) Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Laboratorios Farmaceuticos Rovi's EPS (Diluted)
For the Biotechnology subindustry, Laboratorios Farmaceuticos Rovi's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Laboratorios Farmaceuticos Rovi's PE Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's PE Ratio distribution charts can be found below:
* The bar in red indicates where Laboratorios Farmaceuticos Rovi's PE Ratio falls into.
EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.
EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.63
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Laboratorios Farmaceuticos Rovi EPS (Diluted) Related Terms
Thank you for viewing the detailed overview of Laboratorios Farmaceuticos Rovi's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.
Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Business Description
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XMAD:ROVI has been successfully added to your 